| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6667314 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Feb, 2022
(1 year, 7 months ago) | |
| US7368460 | VIIV HLTHCARE | Tropane derivatives useful in therapy |
Nov, 2022
(9 months ago) | |
|
US7368460 (Pediatric) | VIIV HLTHCARE | Tropane derivatives useful in therapy |
May, 2023
(3 months ago) | |
Selzentry is owned by Viiv Hlthcare.
Selzentry contains Maraviroc.
Selzentry has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Selzentry are:
- US6667314*PED
- US7368460
- US7368460*PED
Selzentry was authorised for market use on 04 November, 2016.
Selzentry is available in solution;oral dosage forms.
Selzentry can be used as method of treating patients infected with ccr5-tropic hiv-1.
The generics of Selzentry are possible to be released after 30 April, 2024.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | Oct 30, 2023 |
| Pediatric Exclusivity (PED) | Apr 30, 2024 |
Drugs and Companies using MARAVIROC ingredient
Market Authorisation Date: 04 November, 2016
Treatment: Method of treating patients infected with ccr5-tropic hiv-1
Dosage: SOLUTION;ORAL
SELZENTRY family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic